Skip to content

Perineural Injection and Supraspinatus Tendenopathy

Perineural Injection Therapy in Treatment of Chronic Supraspinatous Tendinopathy :A Randomized Clinical Trial Among Egyptian Patients .

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03942640
Enrollment
60
Registered
2019-05-08
Start date
2019-06-01
Completion date
2021-01-01
Last updated
2019-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supraspinatus Tendinopathy

Brief summary

Atotal of 150 consecutive patients with chronic supraspinatous tendinopathy were invited to participate in the study .patients were recruited from the out patient clinic of rheumatology and rehabilitation department,Mansoura university hospital a. perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .

Detailed description

Baseline Evaluation All patients were subjected to the following: 1. Thorough History Taking 1. Personal history: collected data include: age, sex, marital status, handedness, special habits and the current occupation. 2. Complaint in the patient's own words. 3. Present History he current symptoms, mode of onset, duration, , factors that may aggravate or relieve pain Characters of pain (dull aching,sharp pain ,burning sensation ,parasthesia). Distribution of pain . Review of systems: symptoms related to rheumatic conditions in particular conditions with predilection for shoulder joint affection. Symptoms suggestive of medical disorders e.g. diabetes mellitus or thyroid dysfunction. 4. Past History Previous significant trauma(direct or occupational) orsugery to shoulder. Previous steroid injection to the shoulder. Previous injection of any type of regenerative medicine (as prp) 2. Thorough General Examination 1. General condition. 2. Vital signs (pulse, blood pressure, respiratory rate, body temperature) 3. Examination of systems (chest,cardiovascular,abdominal,neurological) to identify medical condition that may cause shoulder pain. 3-Muscloskeletal examination <!-- --> 1. General muscloskeletal examination Examination of all joints for : I.deformity,visible swelling or muscle atrophy II.Palpation for tenderness,warmth,palpable swelling either bony enlargement or synovial effusion. III.Abnormalities in range of motion. IV.Diffuse muscloskeletal pain. V.Abnormalities of gait.

Interventions

OTHERsubctaneous perineural injection

Buffered glucose preparation : 2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection

OTHERdeep prolotherapy

The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 20 Years
Healthy volunteers
No

Inclusion criteria

Patients with supraspinatous tendinopathy

Exclusion criteria

-Shoulder joint instability omplete rotator cuff tear Adhesive capsulitis Septic arthritis Malignancy Coagulopathy Connective tissue diseases Spondyloarthropathies Previous corticosteroid injection in the last six months. Previous other forms of regenerative injection therapy (e.g prp injection therapy) in the last six mo

Design outcomes

Primary

MeasureTime frameDescription
change of pain from baselineimmediately before injection,2 monthes after injection,3 monthes after injectionThe VAS-pain score is composed of a continuous horizontal line. This line is 100 mm in length. To measure the intensity of pain, the score is anchored by (0 score = no pain) at one end and (100 score = worst imaginable pain) on the other end. The patient places a mark to the VAS line at the point which represents the intensity of his pain
change of range of motion from base lineimmediately before injection,2 monthes after injection,3 monthes after injectionIII.Examination of passive and active range of motion using goniometer based on the description of norkin and white as following * Abduction ;170 * Adduction :50 * Flexion :165 * Extension:60 * Internal rotation at 90 abduction :70 * External rotation at 90 abduction :100

Secondary

MeasureTime frameDescription
change of function from base lineimmediately before injection,2 monthes after injection,3 monthes after injectionShoulder pain and disability index : a self -administered questionnaire that consists of 2 dimentions ,one for pain and the other for functional activities.

Countries

Egypt

Contacts

Primary ContactReham M. Shaat
rehamshaat@gmail.com01224082636

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026